Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Six Cycles of Docetaxel and Cyclophosphamide or Three Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by Three Cycles of Docetaxel Versus Four Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer

NCT04127019 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04127019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04127019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Six Cycles of Docetaxel and Cyclophosphamide or Three Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by Three Cycles of Docetaxel Versus Four Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Completed
Start date
June 1, 2010
Completion date
June 15, 2017
Enrollment
2,079 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary breast cancer